


THE 9TH BIOSCIENCE ECONOMY CONFERENCE IS SPONSORED BY:



**BANCA DEL
GOTTARDO**



AND ORGANIZED BY:



Capitalife



Siena Financial Services



Canada-Italy Business Council • Commissione Imprenditoriale Italo-Canadese • Conseil commercial Canada-Italie

In collaboration with:



Media Partner:



The 9th Bioscience Economy Conference

September 24, 2003
Geneva – Switzerland

September 25, 2003
Milano – Italy



FOR INFORMATION ON THE CONFERENCE PLEASE CONTACT:
DR. M. BOTTARO, TEL. +39 348 0456 709; e-mail: marco@capitalife.com

THE 9TH BIOSCIENCE ECONOMY CONFERENCE

During the last years, biotech has emerged as one of the most promising businesses for the future of the worldwide economy, attracting investors' and entrepreneurs' interest. A wide range of biotechnological platforms such as gene therapy, monoclonal antibodies, recombinant proteins, drug delivery control, nucleic acid sequencing, bio-informatics and med-tech for different applications are just a few examples of the Bioscience Economy's extraordinary potential to generate new products. International funds have been formed to invest in life sciences and in today's competitive stock market, the need of a direct and personal communication between companies and investors is imperative.

PARTICIPANTS: SHORT COMPANY PROFILE

■ AASTROM BIOSCIENCES, INC.

Aastrom (NasdaqSC:ASTM) is a late-stage development company focused on human cell-based therapies. Aastrom intends to leverage its proprietary ex vivo cell production technology to produce patient-specific cells for stem cell tissue repair and regeneration (bone grafting applications and vascular tissue repair), and for the treatment of cancer (dendritic cell-based vaccines) and other infectious diseases. Aastrom's business is based on its proprietary AastromReplicell™ System, a patented, GMP-compliant integrated system of instrumentation and single-use consumable kits for the commercial production of human cells. For further information, please visit: www.aastrom.com

■ ARQULE, INC.

ArQule (Nasdaq: ARQL), is aiming to create an R&D focus around oncology and inflammation. Building on its recognized leadership in small-molecule chemistry, ArQule is committed to improving the efficiency of pharmaceutical research and development and continue to provide high quality chemistry production and technology support to pharmaceutical partners. In July 2003 the Company announced the proposed acquisition of Cyclis Pharmaceuticals. This will provide ArQule with a portfolio of early stage oncology programs based on "Activated Checkpoint Therapy™" which holds out the hope of targeted, broad spectrum anti-cancer agents. This will compliment ArQule's ongoing research into p38 MAP kinase inhibitors for inflammatory conditions such as rheumatoid arthritis. For further information, please visit www.arqule.com

■ ID BIOMEDICAL, CORPORATION

ID Biomedical (Nasdaq: IDBE ; TSX: IDB) is a biotechnology company focused on the development of proprietary subunit vaccine products, including those based on its Proteosome™ platform intranasal adjuvant/delivery technology. ID Biomedical is developing subunit vaccines for the prevention of a number of different diseases, as well as vaccines against biological warfare agents. The Company's lead products in clinical development are the FluINsure™ intranasal influenza (flu) vaccine and the StreptAvax™ group A streptococcal vaccine. Additionally, the Company has several vaccines in pre-clinical development. For further information, please visit: www.idbiomedical.com

■ NEUROCHEM, INC.

Neurochem is a leading-edge biopharmaceutical company located in Quebec, Canada and listed on the Toronto Stock Exchange (TSX: NRM). Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The Company's staged pipeline of proprietary, disease-modifying, oral products addresses critical unmet medical needs. Fibrillex™, designated an orphan drug, is in a pivotal Phase II/III clinical trial for AA amyloidosis. Alzhemed™ has completed a Phase II clinical trial. Cerebril™ is in a Phase II trial for the prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy. Neurochem is also developing a product for the potential treatment of epileptic seizures induced by traumatic brain injury. For further information, please visit: www.neurochem.com

■ REGENERON PHARMACEUTICALS, INC.

Regeneron (Nasdaq: REGN) is a biopharmaceutical company that discovers, develops, and intends to commercialise therapeutic medicines for the treatment of serious medical conditions. The Company's product pipeline includes product candidates in clinical trials for the treatment of obesity, rheumatoid arthritis and other inflammatory conditions, cancer, and asthma. Axokine is currently in Phase III clinical development for the treatment of obesity. The IL-1 Trap, for which Regeneron recently announced a co-development and co-promotion agreement with Novartis AG, is currently in Phase II clinical development for the treatment of rheumatoid arthritis and is being evaluated in other indications. Regeneron also has an innovative anti-angiogenesis molecule in a Phase I trial for cancer and is expected to begin efficacy studies in 2004. For further information, please visit: www.regeneron.com

THE 9TH BIOSCIENCE ECONOMY CONFERENCE PRELIMINARY PROGRAM

September 24, 2003 - Hotel Warwick - Geneva

- 09:00 Registration and Welcome
- 09:15 Arqule, Inc.
- 10:00 Regeneron Pharmaceuticals, Inc.
- 10:45 Coffee break
- 11:15 Neurochem, Inc.
- 12:00 Buffet
- 12:30 ID Biomedical, Corporation
- 13:30 Conclusion

September 25, 2003 - Palazzo Affari ai Giureconsulti - Milano

- 08:45 Registration and Welcome
- 09:00 Neurochem, Inc.
- 09:40 Aastrom Biosciences, Inc.
- 10:20 Arqule, Inc.
- 11:00 ID Biomedical, Corporation
- 11:40 Regeneron Pharmaceuticals, Inc.
- 12:20 Round Table
- 13:00 Lunch

REGISTRATION INFORMATION

Location: September 24, Geneva, Switzerland
Hotel Warwick, 14 rue de Lausanne

September 25, Milano, Italy
Palazzo Affari ai Giureconsulti, Piazza Mercanti, 2

Language: English

Admission: By invitation, free

Registration: Fax the registration form or send an e-mail to:

Dr.ssa L. Alessandri, Fax: +39 02 34565 339
E-mail: laura.alessandri@circmi.it

Information: Dr. M. Bottaro, Tel.: +39 348 0456 709
E-mail: marco@capitalife.com